- The increase in uric acid excretion early in the course of treatment with uricosuric agents can promote urinary stone or gravel formation.
- urate-lowering disrupts the physical state and/or surface chemical composition of preformed crystal deposits and thus makes the component crystals interactive with local cells competent
- The risk of precipitating urinary stone formation and acute gouty arthritis can be minimized by starting with low doses of antihyperuricemic therapy and by hydration (2 or more L of fluid daily).
- Alkalinization of the urine is, in most patients, unnecessary
Colchicine
(1) Dosing
- 0.6 mg orally once or twice daily for patients with normal renal function.
- Many patients, particularly older individuals, develop loose or diarrheal stools that preclude use of the recommended colchicine dose.
- Satisfactory prophylaxis in such patients is often attained with the lower colchicine doses of 0.6 mg once daily or even every other day.
- reduced to 0.6 mg per day in patients with a creatinine clearance of 35 to 49 mL/min and to 0.6 mg every two to three days in patients with a creatinine clearance of 10 to 34 mL/min.
- not be used in patients with a creatinine clearance <10 mL/min or in patients undergoing dialysis for end stage renal disease.
(2) Duration
- generally given as short-term therapy (ie, for periods not exceeding six months’ duration)
(3) Concerns
- neuromyopathy is a potential complication of chronic therapy, particularly in patients with a reduced creatinine clearance.
- It should be suspected in patients who complain of paresthesias, numbness, and/or weakness.
- Most cases occur in patients treated with daily low dose colchicine for months to years.
- Patients taking HMG-CoA reductase inhibitors (statins) may be at increased risk for colchicine-induced myopathy
NSAID
(1) Dosing
- Indomethacin (25 mg twice daily) appears to be effective for prophylaxis in patients who do not tolerate low dose colchicine, although the data are very limited
- NSAIDs other than indomethacin may also be effective and may be associated with a lower frequency of side effects.
(2) Duration
- Because of potential toxicity, the continued use of colchicine or NSAIDs is not recommended after persistent normouricemia has been achieved with antihyperuricemic drugs.
- In patients without evident tophi, prophylaxis can often be safely discontinued six months after normal serum urate values have been obtained.
(3) Concerns
- Gastrointestinal toxicity is a potential complication of all NSAIDs, and these agents should not be used in patients with moderate or more severe renal impairment
Reference:
1. www.uptodate.com
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.